BIO 2015 Dispatches: Global Biosimilar Companies Face Regulatory Challenges In China
This article was originally published in The Pink Sheet Daily
Executive Summary
Pfizer VP Owen Fields said uncertainty about the need for local clinical data and delays in getting approval to conduct such trials hinder international companies' willingness to include China in a global development program.